ADENOID CYSTIC CARCINOMA

This study tests a new drug called REM-422 in people with advanced adenoid cystic carcinoma (ACC), a rare cancer of the glands. The drug works by breaking down a specific genetic message (MYB) that helps the cancer grow. The goal is to see if the drug is safe and can shrink tumor…

This study tests whether combining two drugs (becotatug vedotin and epirubicin) can shrink a rare type of sinus cancer that has come back and cannot be removed with surgery. About 40 adults with EGFR-positive tumors will receive the treatment to see if it makes the cancer small e…

This study tests a drug called enfortumab vedotin in 34 people with adenoid cystic carcinoma (ACC) that has returned or spread and cannot be cured with other treatments. The main goal is to see if the drug can shrink tumors. Researchers will also track how long it takes for the c…

This study tests the drug nivolumab in people with advanced rare cancers that have a specific marker (PD-L1). The goal is to see if the drug can shrink or control tumors for at least 12 months. About 28 adults who have not responded to standard treatments will take part.

This study tests a new drug called puxitatug samrotecan in 28 people with a rare and aggressive type of salivary gland cancer (adenoid cystic carcinoma subtype I) that has spread or cannot be removed. The goal is to see if the drug is safe and effective. Participants must be 18 o…

This study tests a new approach for a rare sinus cancer that often spreads along nerves. About 100 adults with advanced tumors will receive three sessions of targeted chemotherapy directly into the tumor's blood supply. If the tumor disappears on scans, patients may avoid surgery…

This study tests an experimental drug called VMD-928, taken as a pill, either alone or with pembrolizumab (an immunotherapy), in adults with advanced solid tumors or lymphoma that have stopped responding to standard treatments. The goal is to find safe doses and see if the drug c…

This early-phase study tests a new drug called XMT-1660 in people with advanced solid tumors, including triple-negative breast, ovarian, and endometrial cancers. The main goals are to find the safest dose and check for side effects. About 319 participants will receive the drug to…

This early-phase study tests a new drug called RGT-61159 in people with two types of cancer that have come back or not responded to treatment: adenoid cystic carcinoma (a rare salivary gland cancer) and colorectal cancer. The main goals are to check the drug's safety, find the be…

This early-stage trial tests a new drug, NN3201, designed to attack cancer cells that have a specific marker called c-Kit. The study includes people with advanced or spreading cancers like gastrointestinal stromal tumors (GIST), small-cell lung cancer, and others. The main goal i…

This study tests whether giving a precise, high-dose radiation treatment (SBRT) early can slow the growth of adenoid cystic carcinoma that has spread to a few spots in the body. About 32 adults with 1 to 5 metastatic lesions will receive SBRT to all visible tumors. Researchers wi…